INCYTE CORP (INCY) Stock
INCY has an Alpha Score of 70 out of 100 (moderate), computed on Oct 30, 2026 from 3 of 4 sub-scores. 5 members of Congress disclosed 6 trades in INCY since 2014: 2 purchases and 4 sales, most recently Rob Bresnahan (sale, May 15, 2025). 6 of the hedge funds AlphaScala tracks reported INCY in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Renaissance Technologies's at $398.14M. Company insiders reported 0 open-market buys and 7 sales on SEC Form 4 in the 90 days to Nov 2, 2026. Its trailing P/E ratio is 14.3 and its net margin 27.7% (key statistics as of Oct 22, 2026).
What is INCY's Alpha Score?
How it works →Alpha Score of 70 reflects moderate overall profile with strong momentum, moderate value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 30, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded INCYTE CORP (INCY)?
Most recent: Rob Bresnahan (sale, May 15, 2025); records start Sep 22, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Rob Bresnahan R-PA · House | 2025-05-15 | sale | $1k – $15k |
| Dan Goldman D-NY · House | 2023-03-06 | sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2020-12-22 | sale | $1k – $15k |
| Shelley Moore Capito R-WV · Senate | 2018-11-12 | sale | $1k – $15k |
| Shelley Moore Capito R-WV · Senate | 2017-09-08 | purchase | $1k – $15k |
| Ed Whitfield R-KY · House | 2014-09-22 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 1, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all INCY political trades →Which hedge funds own INCY?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 3.51M | $398.14M | -4% |
| Marshall Wace | 1.31M | $148.52M | +5% |
| Bridgewater Associates Ray Dalio | 168K | $19.07M | +29% |
| Citadel Ken Griffin | 144K | $16.27M | +191% |
| Millennium Management Israel Englander | 83K | $9.39M | -52% |
| Hussman Investment Trust John Hussman | 32K | $3.82M | -25% |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are INCYTE CORP insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 15, 26 | Cagnoni Pablo J | President, Global Head of R&D | SELL | 2.6K | $298K |
| Sep 15, 26 | Cagnoni Pablo J | President, Global Head of R&D | SELL | 9.2K | $1.1M |
| Sep 15, 26 | Cagnoni Pablo J | President, Global Head of R&D | SELL | 14.0K | $1.7M |
| Aug 19, 26 | Cagnoni Pablo J | President, Global Head of R&D | SELL | 10.8K | $1.4M |
| Aug 12, 26 | Cagnoni Pablo J | President, Global Head of R&D | SELL | 10.8K | $1.3M |
| Aug 5, 26 | Cagnoni Pablo J | President, Global Head of R&D | SELL | 10.6K | $1.3M |
| Aug 5, 26 | Mayes Patrick A | EVP & Chief Scientific Officer | SELL | 2.2K | $274K |
| Aug 3, 26 | Mayes Patrick A | EVP & Chief Scientific Officer | SELL | 6.1K | $729K |
| Jul 31, 26 | Cagnoni Pablo J | President, Global Head of R&D | SELL | 15.9K | $1.9M |
| Jul 31, 26 | Mayes Patrick A | EVP & Chief Scientific Officer | SELL | 14.7K | $1.8M |
SEC Form 4 filings as of Nov 2, 2026
See cluster-buy signals across all tickers →What are INCY's key statistics?
Key statistics as of Oct 22, 2026
How does INCY's valuation compare with the Healthcare sector?
| Metric | INCY | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 14.3 | 27.2 | 99 |
| Net margin | 27.71% | 4.85% | 143 |
| Return on equity | 29.60% | 6.68% | 162 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 3, 2026). P/E excludes loss-making companies.
AlphaScala analysis on INCY
Latest 1INCY price chart
Powered by TradingViewWhat does INCYTE CORP do?
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics targeting hematology, oncology, inflammation, and autoimmunity. Its portfolio features key products such as JAKAFI (ruxolitinib), approved for intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; OPZELURA, addressing atopic dermatitis and vitiligo in the dermatology segment; and MONJUVI/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma. Additional offerings include PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor, alongside NIKTIMVO, ZYNYZ, and ICLUSIG, contributing to its expanding hematology and oncology segments. Incyte Corporation also generates royalty revenues from partnered products like Jakavi and Olumiant. The company operates across the United States, Europe, Canada, and Japan, advancing a pipeline of candidates in oncology and immunology to address unmet medical needs. Founded in 1991 and headquartered in Wilmington, Delaware, Incyte Corporation plays a significant role in delivering targeted therapies for complex diseases.